10 research outputs found
SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)
Colorectal cancer (CRC) is the second cause of cancer death in Spain, the objective of this guide published by the Spanish Society of Medical Oncology is to develop a consensus for the diagnosis and management of metastatic disease. The optimal treatment strategy for patients with metastatic CRC should be discussed in a multidisciplinary expert team to select the most appropriate treatment, and integrate systemic treatment and other options such as surgery and ablative techniques depending on the characteristics of the tumour, the patient and the location of the disease and metastases
Ocular surface toxicity of depatuxizumab mafoditin (ABT-414): case reports
The purpose of this study is to report the clinical features and outcomes of ocular surface toxicity following depatuxizumab mafoditin (ABT-414) therapy for unresectable glioblastoma. Ocular signs and symptoms of three patients treated with ABT-414 during a phase III trial for glioblastoma multiforme were evaluated. Both eyes of all patients were damaged during the week after the first infusion of the ABT-414 molecule. In all patients, mild-to-moderate keratitis could be ascertained, along with decreased visual acuity and blurred vision, as well as foreign-body sensation and redness. Symptoms and visual acuity improved 4 weeks. In conclusion, ABT-414 therapy may cause transient ocular surface toxicity. The initiation of artificial tears and lubricant ointment was enough to control the ocular surface signs and symptoms. A multidisciplinary approach, complete ophthalmologic monitorization, and elaboration of protocols are required to adequately manage these patients
Ocular surface toxicity of depatuxizumab mafoditin (ABT-414): case reports.
The purpose of this study is to report the clinical features and outcomes of ocular surface toxicity following depatuxizumab mafoditin (ABT-414) therapy for unresectable glioblastoma. Ocular signs and symptoms of three patients treated with ABT-414 during a phase III trial for glioblastoma multiforme were evaluated. Both eyes of all patients were damaged during the week after the first infusion of the ABT-414 molecule. In all patients, mild-to-moderate keratitis could be ascertained, along with decreased visual acuity and blurred vision, as well as foreign-body sensation and redness. Symptoms and visual acuity improved 4 weeks. In conclusion, ABT-414 therapy may cause transient ocular surface toxicity. The initiation of artificial tears and lubricant ointment was enough to control the ocular surface signs and symptoms. A multidisciplinary approach, complete ophthalmologic monitorization, and elaboration of protocols are required to adequately manage these patients
Bronchiolitis obliterans organizing pneumonia simulating progression in bronquioloalveolar carcinoma
Secondary signet-ring cell tumour of the prostate derived from a primary gastric malignancy
Hipertrofia benigna de próstata : cáncer de próstata : proceso asistencial integrado. 3ª ed
Publicado en la página web de la Consejería de Salud y Bienestar Social: www.juntadeandalucia.es/salud (Consejería de Salud y Bienestar Social / Profesionales / Nuestro Compromiso por la Calidad / Procesos Asistenciales Integrados)YesEn Andalucía, y tal y como se establece en el III Plan Andaluz de Salud, se ha definido como una de las líneas prioritarias de actuación la reducción de la morbilidad,
mortalidad prematura y discapacidad a través del desarrollo de Planes Integrales y de
Procesos Asistenciales Integrados. Teniendo en cuenta que el cáncer de próstata constituye uno de los principales problemas de salud de la población masculina, se ha procedido a la revisión y actualización del
documento anterior (año 2005)incorporando
nuevos aspectos relacionados con dimensiones específicas de calidad